Male Sexual Flashcards

1
Q

Clinical Vignette: A 50-year-old male presents with questions about his sexual response mechanisms. You consider the bulbocavernous reflex as part of his physiological response.

Multiple-Choice Options:
A) Pudendal nerve (motor) is activated
B) Pelvic nerves are activated
C) Thoracolumbar sympathetic neurons are activated
D) Sacral parasympathetic neurons and interneurons are activated

A

Correct Answer: A

In-depth Explanation:

A: The pudendal nerve (motor) is activated, which leads to the bulbocavernous reflex (Correct, based on paragraph 1).
B: Pelvic nerves are associated with low-intensity continuous stimulation and detrusor inhibition, not with noxious, abrupt stimulation.
C: Thoracolumbar sympathetic neurons are involved in high-intensity continuous stimulation, leading to ejaculation.
D: Sacral parasympathetic neurons and interneurons are involved in low-intensity continuous stimulation, leading to penile erection and detrusor inhibition.
Memory Tool: Noxious Abrupt triggers Pudendal Motor: N.A.P.M.

Reference Citation: Based on Table 68.3, paragraph 1.

Rationale: Understanding the spinal reflex mechanisms is crucial for the correct diagnosis and treatment of male sexual function disorders.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Clinical Vignette: A 25-year-old male is concerned about the spontaneity of his erections. You discuss the role of low-intensity continuous stimulation in sexual response.

Multiple-Choice Options:
A) Sacral motor neurons are activated
B) Penile erection occurs
C) Ejaculation occurs
D) Bulbocavernous reflex occurs

A

Correct Answer: B

In-depth Explanation:

A: Sacral motor neurons are activated during noxious, abrupt stimulation, not during low-intensity continuous stimulation.
B: Penile erection occurs in response to low-intensity continuous stimulation (Correct, based on paragraph 2).
C: Ejaculation occurs in response to high-intensity continuous stimulation.
D: Bulbocavernous reflex occurs in response to noxious, abrupt stimulation.
Memory Tool: Low Intensity, Penile Erection: L.I.P.E.

Reference Citation: Based on Table 68.3, paragraph 2.

Rationale: Recognizing the role of low-intensity continuous stimulation is essential for understanding and advising on male sexual response.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Clinical Vignette: A 40-year-old male with a history of urinary incontinence reports that he experiences fewer symptoms during sexual arousal. You ponder the underlying spinal reflexes at play.

Multiple-Choice Options:
A) Sacral motor neurons are responsible
B) Sacral parasympathetic neurons and interneurons activate pudendal nerve
C) Sacral parasympathetic neurons and interneurons activate pelvic nerves
D) Thoracolumbar sympathetic neurons are responsible

A

Correct Answer: C

In-depth Explanation:

A: Sacral motor neurons are responsible for bulbocavernous reflex, not detrusor inhibition.
B: Pudendal nerve activation results in the bulbocavernous reflex, not detrusor inhibition.
C: Pelvic nerves are activated during low-intensity continuous stimulation, leading to detrusor inhibition and bladder neck closure (Correct, based on paragraph 2).
D: Thoracolumbar sympathetic neurons lead to ejaculation, not detrusor inhibition.
Memory Tool: Detrusor Inhibition: Pelvic Nerves for Closure: D.I.P.N.C.

Reference Citation: Based on Table 68.3, paragraph 2.

Rationale: Understanding spinal reflexes that lead to detrusor inhibition helps in managing patients with urinary incontinence who might experience changes during sexual arousal.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Clinical Vignette: A 30-year-old male complains of premature ejaculation. You consider the neuroanatomy behind ejaculation as part of his treatment plan.

Multiple-Choice Options:
A) Sacral motor neurons activate the pudendal nerve
B) Thoracolumbar sympathetic neurons are involved
C) Sacral parasympathetic neurons and interneurons are involved
D) Pelvic nerves cause detrusor inhibition

A

Correct Answer: B

In-depth Explanation:

A: Sacral motor neurons are involved in bulbocavernous reflex but not directly in ejaculation.
B: Thoracolumbar sympathetic neurons are specifically involved in high-intensity continuous stimulation that leads to ejaculation (Correct, based on paragraph 3).
C: Sacral parasympathetic neurons and interneurons are involved in low-intensity stimulation, leading to penile erection.
D: Pelvic nerves are involved in detrusor inhibition, not ejaculation.
Memory Tool: High-Intensity, Thoracolumbar Sympathetic for Ejaculation: H.I.T.S.E.

Reference Citation: Based on Table 68.3, paragraph 3.

Rationale: Understanding the neural pathways for ejaculation can inform treatment plans for conditions like premature ejaculation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Clinical Vignette: A 55-year-old male presents with erectile dysfunction. Upon inquiry, he states that tactile stimulation does not lead to an erection as easily as before. You consider the spinal reflexes involved.

Multiple-Choice Options:
A) Sacral motor neurons are involved
B) Sacral parasympathetic neurons and interneurons activate pelvic nerves
C) Thoracolumbar sympathetic neurons are activated
D) Pudendal nerve (motor) is activated

A

Correct Answer: B

In-depth Explanation:

A: Sacral motor neurons are primarily activated during noxious, abrupt stimulation leading to the bulbocavernous reflex.
B: Sacral parasympathetic neurons and interneurons activate pelvic and cavernous nerves, leading to penile erection during low-intensity continuous stimulation (Correct, based on paragraph 2).
C: Thoracolumbar sympathetic neurons are involved in high-intensity continuous stimulation leading to ejaculation.
D: Pudendal nerve (motor) activation leads to the bulbocavernous reflex, not penile erection.
Memory Tool: Tactile Stimulation for Penile Erection: T.S.P.E.

Reference Citation: Based on Table 68.3, paragraph 2.

Rationale: Accurate knowledge of the neural pathways involved in penile erection is crucial for diagnosis and treatment of erectile dysfunction.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Clinical Vignette: A 28-year-old male has concerns about delayed ejaculation. You evaluate the role of spinal reflexes and associated nerves.

Multiple-Choice Options:
A) Pudendal nerve only
B) Pudendal, pelvic, and cavernous nerves
C) Pelvic and cavernous nerves only
D) Thoracolumbar sympathetic neurons only

A

Correct Answer: B

In-depth Explanation:

A: Pudendal nerve is involved but not solely responsible for ejaculation.
B: High-intensity continuous stimulation activates pudendal, pelvic, and cavernous nerves, leading to ejaculation (Correct, based on paragraph 3).
C: Pelvic and cavernous nerves are involved, but not solely responsible for ejaculation.
D: Thoracolumbar sympathetic neurons are involved in the neural pathway, but they are not nerves.
Memory Tool: High-Intensity to Pudendal, Pelvic, Cavernous: H.I.P.P.C.

Reference Citation: Based on Table 68.3, paragraph 3.

Rationale: Knowing the array of nerves involved in ejaculation is essential for diagnosing and treating ejaculatory disorders.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Clinical Vignette: A 60-year-old male is evaluated for postoperative urinary retention. You’re contemplating the role of noxious, abrupt stimulation on bladder function.

Multiple-Choice Options:
A) Detrusor inhibition and closure of bladder neck occur
B) Bladder contraction occurs
C) Penile erection occurs
D) Bulbocavernous reflex is triggered

A

Correct Answer: D

In-depth Explanation:

A: Detrusor inhibition and bladder neck closure occur with low-intensity continuous stimulation, not with noxious, abrupt stimulation.
B: Bladder contraction is not mentioned in the table regarding noxious, abrupt stimulation.
C: Penile erection is associated with low-intensity continuous stimulation.
D: Noxious, abrupt stimulation activates sacral motor neurons leading to the bulbocavernous reflex (Correct, based on paragraph 1).
Memory Tool: Noxious Abrupt for Bulbocavernous: N.A.B.

Reference Citation: Based on Table 68.3, paragraph 1.

Rationale: Understanding the reflexes associated with noxious, abrupt stimulation can guide you in managing urinary retention or other bladder-related issues.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Clinical Vignette: A 35-year-old male complains of loss of penile sensation. During physical examination, you plan to evaluate the bulbocavernous reflex.

Multiple-Choice Options:
A) Sacral parasympathetic neurons and interneurons
B) Thoracolumbar sympathetic neurons
C) Sacral motor neurons
D) Pelvic nerves

A

Correct Answer: C

In-depth Explanation:

A: Sacral parasympathetic neurons and interneurons are involved in low-intensity continuous stimulation, not in bulbocavernous reflex.
B: Thoracolumbar sympathetic neurons are involved in high-intensity continuous stimulation leading to ejaculation.
C: Sacral motor neurons are activated during noxious, abrupt stimulation and lead to the bulbocavernous reflex (Correct, based on paragraph 1).
D: Pelvic nerves are involved in low-intensity continuous stimulation leading to detrusor inhibition and penile erection.
Memory Tool: Bulbocavernous Reflex: Sacral Motor: B.R.S.M.

Reference Citation: Based on Table 68.3, paragraph 1.

Rationale: Identifying the neurons involved in the bulbocavernous reflex is key for diagnosis and treatment planning in conditions involving loss of penile sensation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Clinical Vignette: A 45-year-old male patient presents with complaints of delayed ejaculation. He is interested in exploring pharmacological options.

Multiple-Choice Options:
A. Cabergoline 0.5–2.0 mg every 3 days
B. Pramipexole 0.5 mg
C. Amantadine 100–200 mg bid
D. Bupropion 300 mg bid

A

Correct Answer: A

In-depth Explanation:

A (Correct): Cabergoline at 0.5–2.0 mg every 3 days is listed as an option for delayed ejaculation (Table 71.7).
B (Incorrect): Pramipexole should be 0.125–0.25 mg, not 0.5 mg as listed (Table 71.7).
C (Incorrect): Amantadine is for two days before coitus at a range of 100–400 mg or 100–200 mg bid (Table 71.7).
D (Incorrect): Bupropion should be 150 mg daily or bid, not 300 mg bid as listed (Table 71.7).
Memory Tool: “CAB” - Cabergoline Always Better for delayed ejaculation (Not actually always better, but it helps you remember).

Specific Reference Citation: Table 71.7

Rationale: Understanding the proper dosages and drugs for specific urological conditions such as delayed ejaculation is essential for patient management.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Clinical Vignette: A 35-year-old male has been experiencing issues with anejaculation and is interested in medications he can take as needed, rather than daily. Which drug could he take as needed only before coitus?

Multiple-Choice Options:
A. Amantadine
B. Pseudoephedrine
C. Cyproheptadine
D. Buspirone

A

Correct Answer: C

In-depth Explanation:

A (Incorrect): Amantadine can be taken daily but also for two days before coitus (Table 71.7).
B (Incorrect): Pseudoephedrine is to be taken the day before and the day of coitus, making it not strictly as-needed (Table 71.7).
C (Correct): Cyproheptadine can be taken 3–4 hours before coitus, making it a true as-needed option (Table 71.7).
D (Incorrect): Buspirone is a daily treatment with dosages of 5–15 mg bid (Table 71.7).
Memory Tool: “Cy-pronounce-it ‘As-needed’” for Cyproheptadine.

Specific Reference Citation: Table 71.7

Rationale: Identifying as-needed versus daily treatment options can be crucial for tailoring treatment to individual patient preferences and lifestyles.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Clinical Vignette: A 52-year-old male patient has been experiencing anejaculation. He inquires about intranasal medication options.

Multiple-Choice Options:
A. Amantadine
B. Oxytocin
C. Bupropion
D. Reboxetine

A

Correct Answer: B

In-depth Explanation:

A (Incorrect): Amantadine is not intranasal; it is taken orally (Table 71.7).
B (Correct): Oxytocin is the only drug listed that can be administered as 24 IU intranasal during coitus (Table 71.7).
C (Incorrect): Bupropion is an oral medication and is not administered intranasally (Table 71.7).
D (Incorrect): Reboxetine is also an oral medication, not an intranasal one (Table 71.7).
Memory Tool: “Oxy-IN” - Oxytocin is Intranasal.

Specific Reference Citation: Table 71.7

Rationale: Knowing the route of administration for different medications is crucial for personalized patient care.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Clinical Vignette: A 30-year-old man presents with delayed ejaculation. He is looking for a medication that he could use daily.

Multiple-Choice Options:
A. Reboxetine
B. Pseudoephedrine
C. Pramipexole
D. Buspirone

A

Correct Answer: D

In-depth Explanation:

A (Incorrect): Reboxetine is not listed under daily options (Table 71.7).
B (Incorrect): Pseudoephedrine is taken the day before coitus and on the day of coitus, not daily (Table 71.7).
C (Incorrect): Pramipexole is not specified to be taken daily (Table 71.7).
D (Correct): Buspirone is listed as 5–15 mg bid, suitable for daily use (Table 71.7).
Memory Tool: “Daily Bus” - Buspirone for daily use.

Specific Reference Citation: Table 71.7

Rationale: Tailoring daily medication options for conditions like delayed ejaculation can help enhance a patient’s quality of life.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Clinical Vignette: A 40-year-old male patient presents with delayed ejaculation and prefers a medication that he only needs to take before sexual activities. Which medication could he consider?

Multiple-Choice Options:
A. Pseudoephedrine
B. Reboxetine
C. Pramipexole
D. Amantadine

A

Correct Answer: A

In-depth Explanation:

A (Correct): Pseudoephedrine is taken 60–120 mg q6h the day before coitus and then twice on the day of coitus (Table 71.7).
B (Incorrect): Reboxetine is not specified for as-needed use before coitus (Table 71.7).
C (Incorrect): Pramipexole is not indicated as an as-needed medication for coitus (Table 71.7).
D (Incorrect): Amantadine requires two days of pre-treatment before coitus, not ideal for spontaneous activity (Table 71.7).
Memory Tool: “Pseudo-pre” for Pseudoephedrine is to be taken pre-coitus.

Specific Reference Citation: Table 71.7

Rationale: Choosing the appropriate as-needed medication can significantly impact patient satisfaction and compliance.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Clinical Vignette: A 29-year-old male is diagnosed with delayed ejaculation. The physician is considering medications with a dosing schedule that involves taking the drug twice a day. Which of the following is an option?

Multiple-Choice Options:
A. Amantadine
B. Cyproheptadine
C. Buspirone
D. Oxytocin

A

Correct Answer: C

In-depth Explanation:

A (Incorrect): Amantadine has a dosing option of 100–200 mg bid, but it is also taken for two days before coitus, making it less ideal for a strict bid schedule (Table 71.7).
B (Incorrect): Cyproheptadine is taken 3–4 hours before coitus and doesn’t have a bid schedule (Table 71.7).
C (Correct): Buspirone can be taken as 5–15 mg bid, fitting the twice-a-day requirement (Table 71.7).
D (Incorrect): Oxytocin is administered intranasally during coitus and doesn’t follow a bid schedule (Table 71.7).
Memory Tool: “Bus-bid” for Buspirone is taken bid.

Specific Reference Citation: Table 71.7

Rationale: Being able to recommend medications with specific dosing schedules is important for physicians to improve patient adherence.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Vignette: A 45-year-old man presents with Peyronie’s Disease. He is concerned about medication options and asks about Potaba.

Options:
A) Increases serotonin levels
B) Increases monoamine oxidase activity
C) Blocks the TGF-β1–mediated pathway of inflammation
D) Induces the production of TGF-β

A

Correct Answer: B

Explanation:

A) Incorrect. Potaba decreases serotonin levels, not increases.
B) Correct. Potaba increases monoamine oxidase activity, which results in a decrease of serotonin levels and enhancement of the antifibrotic properties of tissues.
C) Incorrect. This is the mechanism for Pentoxifylline.
D) Incorrect. This is the mechanism for Tamoxifen.
Memory Tool: Potaba sounds like “Mono-ba,” reminding you that it increases monoamine oxidase activity.

Reference Citation: Table 73.1, Oral Agents for Peyronie’s Disease

Rationale: Understanding the mechanism of action for different medications is critical for choosing the most appropriate treatment for Peyronie’s Disease.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Vignette: A 50-year-old patient with Peyronie’s disease asks about the safety of intralesional Verapamil.

Options:
A) Alopecia
B) Thromboembolism
C) Nausea and penile pain
D) Seizures

A

Correct Answer: C

Explanation:

A) Incorrect. Alopecia is an adverse effect of Tamoxifen.
B) Incorrect. Thromboembolism is not an adverse effect of Verapamil.
C) Correct. Adverse effects of Verapamil include nausea, lightheadedness, penile pain, and ecchymoses.
D) Incorrect. Seizures are an adverse effect of Carnitine.
Memory Tool: “Very Painful Pen” can remind you that Verapamil can cause Penile Pain.

Reference Citation: Table 73.2, Intralesional Agents for Peyronie’s Disease

Rationale: Being aware of the adverse effects of intralesional agents like Verapamil helps in educating patients and making informed treatment choices.

17
Q

Vignette: A 60-year-old male asks if external force application methods could be beneficial for his Peyronie’s Disease.

Options:
A) No evidence of effectiveness
B) Decreases plaque volume but not curvature
C) Decreases curvature, increases length, and girth
D) Only provides pain relief

A

Correct Answer: C

Explanation:

A) Incorrect. Penile traction has shown effectiveness in multiple outcomes.
B) Incorrect. Penile traction has been shown to decrease curvature.
C) Correct. Penile traction can decrease curvature, increase length and girth, and also offer other benefits like pain relief.
D) Incorrect. Penile traction offers multiple benefits beyond just pain relief.
Memory Tool: “Penile Traction = Positive Transformation” can remind you that it changes multiple factors positively.

Reference Citation: Table 73.3, External Force Application for Peyronie’s Disease

Rationale: Knowing the effectiveness of external force application methods provides alternative treatment options, especially for patients reluctant to undergo pharmacotherapy.

18
Q

Vignette: A 42-year-old male with Peyronie’s Disease asks about the effectiveness of Vitamin E as a treatment option.

Options:
A) Decreases curvature
B) No benefit
C) Decreased plaque size
D) Improvement in quality of erection

A

Correct Answer: B

Explanation:

A) Incorrect. Vitamin E does not have a benefit in decreasing curvature.
B) Correct. The study outcomes for Vitamin E have shown no benefit.
C) Incorrect. Vitamin E does not decrease plaque size.
D) Incorrect. Vitamin E does not improve the quality of erection.
Memory Tool: “Vitamin E = Very Empty” to remind you that Vitamin E has shown no benefit.

Reference Citation: Table 73.1, Oral Agents for Peyronie’s Disease

Rationale: Knowing the lack of effectiveness of Vitamin E helps guide patient expectations and decision-making for treatment.

19
Q

Vignette: A 58-year-old man asks if there is an intralesional agent that could selectively degrade collagen types.

Options:
A) Nicardipine
B) Verapamil
C) Interferon alfa-2b
D) Clostridial collagenase

A

Correct Answer: D

Explanation:

A) Incorrect. Nicardipine is more effective in reducing glycosaminoglycan biosynthesis, not collagen degradation.
B) Incorrect. Verapamil inhibits fibroblast proliferation and extracellular matrix protein synthesis.
C) Incorrect. Interferon alfa-2b decreases plaque fibroblast proliferation.
D) Correct. Clostridial collagenase selectively degrades collagen types I and III in connective tissues.
Memory Tool: “Close to Collagen” can remind you that Clostridial Collagenase degrades collagen.

Reference Citation: Table 73.2, Intralesional Agents for Peyronie’s Disease

Rationale: Identifying agents that target collagen types can provide more specialized treatment options.

20
Q

Vignette: A 55-year-old patient with Peyronie’s Disease inquires about the safety of using vacuum therapy.

Options:
A) Temporary erythema at the electrode site
B) Local petechiae and ecchymoses
C) Development of PD, urethral bleeding, skin necrosis, and penile ecchymosis
D) Possible malignant change

A

Correct Answer: C

Explanation:

A) Incorrect. Erythema at the electrode site is an adverse effect of Electromotive drug administration.
B) Incorrect. Local petechiae and ecchymoses are adverse effects of Extracorporeal shock wave therapy.
C) Correct. Vacuum therapy can lead to the development of Peyronie’s Disease, urethral bleeding, skin necrosis, and penile ecchymosis.
D) Incorrect. Possible malignant change is an adverse effect of Radiation therapy.
Memory Tool: “Very Terrifying Consequences” to remember that Vacuum Therapy can lead to some serious adverse effects.

Reference Citation: Table 73.3, External Force Application for Peyronie’s Disease

Rationale: Awareness of the adverse effects of treatments like Vacuum Therapy assists in providing comprehensive patient counseling.

21
Q

Vignette: A 50-year-old male patient with Peyronie’s Disease asks about the side effects of Potaba, which was recommended as a treatment option for him.

Options:
A) Seizures, diarrhea
B) Nausea, vomiting, dyspepsia
C) Anorexia, nausea, fever, skin rash, hypoglycemia, acute hepatitis
D) Penile pain, ecchymoses

A

Correct Answer: C

Explanation:

A) Incorrect. Seizures and diarrhea are adverse effects of Carnitine, not Potaba.
B) Incorrect. These are the adverse effects of Pentoxifylline.
C) Correct. Potaba has multiple side effects like anorexia, nausea, fever, skin rash, hypoglycemia, and acute hepatitis.
D) Incorrect. Penile pain and ecchymoses are adverse effects associated with Verapamil.
Memory Tool: “A No-Fun Rash” to remember that Potaba can result in Anorexia, Nausea, Fever, skin Rash, among other symptoms.

Reference Citation: Table 73.1, Oral Agents for Peyronie’s Disease

Rationale: Detailed awareness of the adverse effects of medications like Potaba can assist in making informed treatment choices.

22
Q

Vignette: A 60-year-old male patient with Peyronie’s Disease is interested in treatments that have shown significant reduction in pain and plaque size.

Options:
A) Verapamil
B) Nicardipine
C) Interferon alfa-2b
D) Clostridial collagenase

A

Correct Answer: B

Explanation:

A) Incorrect. Verapamil reduces curvature and plaque-associated penile narrowing but does not specifically mention reduction in pain or plaque size.
B) Correct. Nicardipine has shown a reduction in pain, improvement in IIEF-5 score, and reduction of plaque size.
C) Incorrect. Interferon alfa-2b reduces curvature but does not specifically mention reduction in pain or plaque size.
D) Incorrect. Clostridial collagenase decreases curvature but does not mention reduction in pain or plaque size specifically.
Memory Tool: “Nice and Cozy” for Nicardipine, reminding you it’s nice for pain relief and cozy for reducing plaque.

Reference Citation: Table 73.2, Intralesional Agents for Peyronie’s Disease

Rationale: Knowing the distinct advantages of certain agents, such as Nicardipine, helps tailor treatment plans for specific patient concerns.

23
Q

Vignette: A 46-year-old male patient with Peyronie’s Disease wants to understand how penile traction works before considering it as a treatment option.

Options:
A) Direct damage to the penile plaque
B) Increases matrix metalloproteinases involved in collagen degradation
C) Anti-inflammatory effects
D) Bypasses hepatic metabolism

A

Correct Answer: B

Explanation:

A) Incorrect. Direct damage to the penile plaque is the mechanism for Extracorporeal shock wave therapy.
B) Correct. Penile Traction increases matrix metalloproteinases involved in collagen degradation.
C) Incorrect. Anti-inflammatory effects are associated with Radiation therapy.
D) Incorrect. Bypassing hepatic metabolism is associated with Electromotive drug administration.
Memory Tool: “Traction breaks the chain,” to remind you that Penile Traction works by breaking down collagen chains.

Reference Citation: Table 73.3, External Force Application for Peyronie’s Disease

Rationale: Understanding the underlying mechanism helps in the selection and patient education of treatments like Penile Traction.

24
Q

Vignette: A 55-year-old male patient is considering Vitamin E as a potential treatment for his Peyronie’s Disease. He inquires about the efficacy of this option.

Options:
A) Decreased plaque size and curvature
B) No benefit
C) Decreased curvature in 33% of patients
D) Reduction of pain, improvement in IIEF-5 score, and reduction of plaque size

A

Correct Answer: B

Explanation:

A) Incorrect. There is no evidence that Vitamin E decreases plaque size or curvature.
B) Correct. Studies show that Vitamin E has no benefit for Peyronie’s Disease.
C) Incorrect. This outcome is related to Pentoxifylline, not Vitamin E.
D) Incorrect. This is related to Nicardipine, not Vitamin E.
Memory Tool: “E is for Empty promises” to remember that Vitamin E has no benefit in treating Peyronie’s Disease.

Reference Citation: Table 73.1, Oral Agents for Peyronie’s Disease

Rationale: Understanding which treatments are ineffective is equally critical for personalized patient care.

25
Q

Question 11: Intralesional Agents for Peyronie’s Disease
Topic: Adverse Effects of Verapamil

Vignette: A 48-year-old patient asks about the side effects of Verapamil for treating Peyronie’s Disease.

Options:
A) Sinusitis, flulike symptoms
B) No severe side effects such as hypotension or other cardiovascular events
C) Nausea, lightheadedness, penile pain, ecchymoses
D) Myelosuppression, diarrhea

A

Correct Answer: C

Explanation:

A) Incorrect. These are the adverse effects of Interferon alfa-2b.
B) Incorrect. This statement is related to Nicardipine.
C) Correct. The side effects of Verapamil include nausea, lightheadedness, penile pain, and ecchymoses.
D) Incorrect. Myelosuppression and diarrhea are associated with Colchicine.
Memory Tool: “Very Light Pains Everywhere” to remember that Verapamil can cause Nausea, Lightheadedness, Penile pain, and Ecchymoses.

Reference Citation: Table 73.2, Intralesional Agents for Peyronie’s Disease

Rationale: Knowledge of specific adverse effects is crucial for patient counseling and informed decision-making.

26
Q

Vignette: A 52-year-old male patient is intrigued by the efficacy of penile traction but is cautious about potential side effects.

Options:
A) Temporary erythema at the electrode site
B) Erythema in the balanopreputial sulcus, discomfort
C) Possible malignant change, increased risk for ED in elderly
D) Local petechiae and ecchymoses

A

Correct Answer: B

Explanation:

A) Incorrect. This is associated with Electromotive drug administration.
B) Correct. The adverse effects of Penile Traction include erythema in the balanopreputial sulcus and discomfort.
C) Incorrect. This is related to Radiation therapy.
D) Incorrect. Local petechiae and ecchymoses are associated with Extracorporeal shock wave therapy.
Memory Tool: “Better Be Erythema and Discomfort” for “Balanopreputial Erythema and Discomfort” when considering Penile Traction.

Reference Citation: Table 73.3, External Force Application for Peyronie’s Disease

Rationale: Being well-informed about the potential downsides helps patients to make balanced decisions about treatment options.

27
Q

Vignette: A 50-year-old male wants to know how effective Interferon alfa-2b is for Peyronie’s Disease.

Options:
A) Decrease in curvature of 27%
B) Decrease in penile curvature by 34%
C) Length increased 0.5–2.0 cm
D) No clinical benefit

A

Correct Answer: A

Explanation:

A) Correct. Interferon alfa-2b showed a decrease in curvature of 27%.
B) Incorrect. This outcome is related to Clostridial collagenase.
C) Incorrect. This outcome is associated with Penile traction.
D) Incorrect. “No clinical benefit” is an outcome for various other treatments, not Interferon alfa-2b.
Memory Tool: “Interferon Alfa Aces with 27%” to remember its 27% effectiveness in decreasing curvature.

Reference Citation: Table 73.2, Intralesional Agents for Peyronie’s Disease

Rationale: The effectiveness of a drug in clinical studies provides valuable data for treatment selection.

28
Q

Vignette: A 45-year-old male asks if Extracorporeal Shock Wave Therapy will help reduce his penile curvature caused by Peyronie’s Disease.

Options:
A) Decrease in penile curvature by 34%
B) Reduction in angle of curvature by 5–25 degrees
C) Improvements in pain, IIEF-5 score, and mean QoL score; no curvature reduction
D) Decrease in curvature of 27%

A

Correct Answer: C

Explanation:

A) Incorrect. This outcome is related to Clostridial collagenase.
B) Incorrect. This outcome is associated with Vacuum therapy.
C) Correct. Extracorporeal Shock Wave Therapy improves pain and other scores but doesn’t reduce curvature.
D) Incorrect. This is the outcome for Interferon alfa-2b.
Memory Tool: “Extra Shock Gives Comfort, not Curves” to remember that it improves comfort but not curvature.

Reference Citation: Table 73.3, External Force Application for Peyronie’s Disease

Rationale: Setting realistic expectations for treatment outcomes is crucial for patient satisfaction.

29
Q

Vignette: A 55-year-old male with Peyronie’s Disease is considering taking Vitamin E and inquires about potential side effects.

Options:
A) Anorexia, nausea, fever
B) Possible cerebrovascular events, nausea
C) Seizures, diarrhea, nausea
D) Myelosuppression, diarrhea, nausea

A

Correct Answer: B

Explanation:

A) Incorrect. These side effects are associated with Potaba.
B) Correct. Possible cerebrovascular events and nausea are side effects of Vitamin E.
C) Incorrect. These are the side effects of Carnitine.
D) Incorrect. These side effects are related to Colchicine.
Memory Tool: “Vitamin E is B, Be careful of your Brain” to remember the cerebrovascular events.

Reference Citation: Table 73.1, Oral Agents for Peyronie’s Disease

Rationale: Recognizing potential side effects can help in informed decision-making for treatment options.